Corcept Therapeutics Incorporated (NasdaqCM: CORT)
Health Care · Pharmaceuticals · US
$122.75
-0.40% today · +79.1% 1Y
Corcept Therapeutics Incorporated (NasdaqCM: CORT) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $13.32B and employs 730 people.
Over the last twelve months the share price has gained 79.1%, trading between 28.66 and 122.21.
Tweenvest scores Corcept Therapeutics Incorporated across four factors: quality 71/100, value 11/100, growth 47/100. Its strongest factor is quality.
CORT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $13.32B
- Revenue (TTM)
- $830.81M
- P/E
- 271.66
- EPS
- 0.45
- Dividend yield
- —
- Beta (5Y)
- 0.46
- 52-week high
- $122.21
- 52-week low
- $28.66
- Avg volume (3M)
- —
- Shares outstanding
- 108.10M
- Employees
- 730
- Next earnings
- —
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
- ISIN
- US2183521028
- Founded
- 1998
- Listed since
- Apr 14, 2004
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,246.46 | -0.04% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $272.89 | -0.05% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $155.63 | +3.30% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.40 | +1.54% |
Figures last refreshed Aug 18, 2026.